IRIS PubliCatt

Lombardi, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.456
EU - Europa 1.055
AS - Asia 427
AF - Africa 13
OC - Oceania 4
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 2.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.449
SE - Svezia 356
IT - Italia 199
CN - Cina 154
PL - Polonia 115
SG - Singapore 114
IE - Irlanda 95
FR - Francia 75
DE - Germania 70
ID - Indonesia 63
IN - India 53
FI - Finlandia 34
RU - Federazione Russa 33
GB - Regno Unito 20
BE - Belgio 15
HK - Hong Kong 12
IR - Iran 10
CI - Costa d'Avorio 9
NL - Olanda 9
UA - Ucraina 6
CH - Svizzera 5
CZ - Repubblica Ceca 5
ES - Italia 5
JP - Giappone 5
CA - Canada 4
TW - Taiwan 4
AU - Australia 3
VN - Vietnam 3
AT - Austria 2
CL - Cile 2
EU - Europa 2
MY - Malesia 2
NG - Nigeria 2
PA - Panama 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BR - Brasile 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
EG - Egitto 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
KR - Corea 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MX - Messico 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TR - Turchia 1
Totale 2.962
Salva come PNG Salva come JPEG
Città #
Chandler 476
Ashburn 118
Warsaw 114
New York 103
Dublin 92
Singapore 79
Milan 66
Jakarta 63
San Mateo 55
Boston 41
Princeton 41
Beijing 40
Marseille 39
Wilmington 34
Rome 32
Helsinki 30
Ann Arbor 25
Fairfield 25
Moscow 25
Nanjing 24
Woodbridge 20
Seattle 17
Jacksonville 16
Brussels 15
Houston 15
Pune 15
Cambridge 14
Augusta 12
Cattolica 12
Redwood City 12
Los Angeles 11
Dearborn 10
Abidjan 9
Amsterdam 9
Hong Kong 8
London 8
Andover 7
Nanchang 7
Norwalk 6
Turin 6
Bologna 5
Hangzhou 5
Kish 5
Brno 4
Carate Brianza 4
Edinburgh 4
Jiaxing 4
Lancaster 4
Mountain View 4
Tianjin 4
Tokyo 4
Atlanta 3
Bremen 3
Cagliari 3
Chicago 3
Dong Ket 3
Düsseldorf 3
Fort Worth 3
Guangzhou 3
Hefei 3
Jinan 3
Leawood 3
Phoenix 3
Sacramento 3
Shenyang 3
Springfield 3
Toronto 3
Alexandria 2
Bern 2
Boardman 2
Brea 2
Castano Primo 2
Cedar Knolls 2
Central District 2
Changsha 2
Chennai 2
Chiusi 2
Ciampino 2
Falkenstein 2
Fuzhou 2
Hanover 2
Las Rozas de Madrid 2
Lawrence 2
Madrid 2
Manerbio 2
Milton 2
Munich 2
Panama City 2
Poggio A Caiano 2
Redmond 2
Robbiate 2
Santiago 2
Stockholm 2
Taipei 2
Tarquinia 2
Almaty 1
Ardabil 1
Auburn Hills 1
Bangalore 1
Cairo 1
Totale 1.907
Salva come PNG Salva come JPEG
Nome #
Evaluation of the effect of a floxed Neo cassette within the dystroglycan (Dag1) gene 255
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 95
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 92
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 84
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 84
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 81
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 76
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 72
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 71
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study 71
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 71
Sarilumab use in severe SARS-CoV-2 pneumonia 71
Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line 69
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 67
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 67
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 66
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 66
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 64
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 64
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 63
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 60
Seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak 58
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 57
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 56
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 55
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 55
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 55
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital 54
No evidence of SARS-CoV-2 circulation in HIV-infected patients between December 2019 and February 2020 in Rome, Italy 52
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice 52
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV 49
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 48
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 48
Evaluation of doravirine-based regimen population target in a large Italian clinical center 46
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting 45
Home Care Assistance: Has Covid-19 had an Impact on the Complex Management of HIV Patients? 41
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 41
Quantification of total hiv dna as a marker to measure viral reservoir: Methods and potential implications for clinical practice 40
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort study 39
Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors 36
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 34
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 33
Implementing a Personalized Antimicrobial Stewardship Program for Women with Gynecological Cancers and Healthcare-Associated Infections 33
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 32
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy 32
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 32
Short Communication: Efficacy and Safety of Dolutegravir plus Lamivudine as a First-Line Regimen in Clinical Practice 31
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 29
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 25
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 18
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 16
Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype 16
Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome 13
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 10
Characteristics of mental health interventions in a cohort of Italian PLWH over the last five years: impact of HIV disease and outbreak of COVID-19 pandemic 10
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 9
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy 9
Changes in Metabolic Profile in PLWHIV Switching to Doravirine-Based Regimen 8
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops 8
Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report 7
Clinical presentation of human monkeypox virus infection during the 2022 outbreak: descriptive case series from a large italian Research Hospital 6
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 6
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study 5
Totale 3.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020203 0 0 12 29 7 19 17 10 15 8 80 6
2020/2021144 25 11 5 7 14 10 9 2 12 12 30 7
2021/2022464 10 3 10 51 10 6 38 78 14 40 56 148
2022/20231.177 163 179 93 173 75 139 63 92 134 8 46 12
2023/2024666 16 143 17 63 23 134 46 15 18 25 96 70
2024/2025180 21 18 141 0 0 0 0 0 0 0 0 0
Totale 3.058